Results 211 to 220 of about 47,567 (220)

Acute myeloid leukemia management and research in 2025

Ca-A Cancer Journal for Clinicians
Courtney D Dinardo, Naval G Daver, Jessica K Altman   +2 more
exaly  

Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

New England Journal of Medicine
Mark Litzow, Jacob M Rowe, Matthew J Wieduwilt   +2 more
exaly  

Hairy Cell Leukemia: Diagnosis and Management

Ca-A Cancer Journal for Clinicians, 1978
exaly  

Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 28/06/2017, Revision: 3, Status: Authorised

Case Medical Research, 2018
openaire   +1 more source

Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 28/06/2017, Revision: 4, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source

Human medicines European public assessment report (EPAR): Sprycel, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 32, Status: Authorised

Case Medical Research, 2019
openaire   +2 more sources

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

New England Journal of Medicine
Sumit Gupta, Rachel E Rau, Karen R Rabin
exaly  

Human medicines European public assessment report (EPAR): Jylamvo, methotrexate, Arthritis, Psoriatic,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Psoriasis,Arthritis, Rheumatoid,Arthritis, Date of authorisation: 29/03/2017, Revision: 4, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source

Human medicines European public assessment report (EPAR): Jylamvo, methotrexate, Arthritis, Psoriatic,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Psoriasis,Arthritis, Rheumatoid,Arthritis, Date of authorisation: 29/03/2017, Revision: 2, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source

Human medicines European public assessment report (EPAR): Imatinib Actavis, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 17/04/2013, Revision: 12, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source